Summit Therapeutics
7 articles
Industry NewsSummit Therapeutics / AkesoBioSpace
FDA rejects Summit's ivonescimab in EGFR-mutated lung cancer, citing missing survival benefit
- FDA issued a complete response letter for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy, which would have been the first US approval of a PD-1xVEGF bispecific.
- The agency said progression-free survival gains without a statistically significant overall survival benefit do not show a positive benefit-risk profile; HARMONi missed its OS endpoint, and Summit's September follow-up analysis did not change that.
- Summit says it will keep building evidence across several NSCLC settings and gave no next step for this indication; partner Akeso already markets the drug in China.
The rejection was widely expected, and the lesson is about trial design: a PFS-only win in a post-TKI setting will not clear today's FDA. The bigger pivot is the Western first-line HARMONi-3 readout, which now carries the whole US thesis, and the combination partners lined up with Summit (AstraZeneca, Pfizer, Revolution Medicines) are holding options, not commitments.
Industry NewsSummit Therapeutics / Capricor / Vertex PharmaceuticalsBioSpace
FDA's Crowded November: Ivonescimab, Deramiocel and Povetacicept Face Verdicts
- Summit's ivonescimab for EGFR-mutated lung cancer after TKI therapy is due by November 14; it would be the first PD-1xVEGF bispecific cleared in the US. Capricor's DMD cell therapy deramiocel is due November 22 after a 9-3 negative advisory vote.
- Vertex's povetacicept in IgA nephropathy is due by November 30; rivals from Novartis and Vera are already approved. At least 11 action dates fall this month.
Ivonescimab is the cleanest read-through: a progression-free-survival win without a significant overall-survival result at filing, so approval would show how much the FDA discounts a later nominal survival signal. Capricor is the opposite, a negative panel and a prior rejection. Povetacicept is a late entrant, so label and pricing decide how fast it takes share.
Industry NewsSummit TherapeuticsBioSpace
Pfizer, AstraZeneca, Revolution Medicines line up ivonescimab combos ahead of FDA decision
- AstraZeneca will test ivonescimab with Datroway (TROP2 ADC, with Daiichi Sankyo) starting in first-line triple-negative breast cancer, and with CLDN18.2 ADC sone-ve in GI cancers; Pfizer plans pairings with its vedotin ADCs including Padcev.
- Revolution Medicines offered its RAS(ON) inhibitors, among them zoldonrasib and elironrasib, as partners for RAS-mutant tumors; Summit says more collaborations are under discussion.
- FDA is due to decide on ivonescimab in second-line non-squamous NSCLC on November 14; final HARMONi-3 progression-free survival data are expected before year-end.
- Analysts at Mizuho and Stifel are bullish, while AstraZeneca notes most positive data are China-only.
Partners queuing for combo trials before any US approval is a bet that PD-1xVEGF becomes a backbone, and it gives Summit leverage beyond monotherapy sales. But each ADC pairing multiplies toxicity and dosing unknowns, and AstraZeneca's China-only caveat hints that a Western HARMONi-3 readout, not the November 14 decision, is the real test of the backbone thesis.
Industry NewsAkeso / Summit TherapeuticsEndpoints News
Akeso details ivonescimab's survival win in biliary tract cancer, a China-only trial
- Akeso presented HARMONi-GI1 at ESMO 2026: its PD-1xVEGF bispecific ivonescimab plus chemotherapy against durvalumab plus chemotherapy in first-line advanced biliary tract cancer.
- The 682-patient study ran in China only and was sponsored and analyzed by Akeso; overall survival was the key result.
- Summit Therapeutics holds rights outside China, and the data are already prompting Keytruda comparisons.
An overall-survival win over an anti-PD-1/L1 backbone is the claim PD-1xVEGF bispecifics need, and biliary cancer is a small, low-risk place to show it. But a China-only, Akeso-run trial will not settle Western regulators, so the value to Summit hinges on global trials such as its lung program, not on this readout.
Industry NewsSummit Therapeutics / AstraZeneca / Daiichi SankyoEndpoints News
Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC
- Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
- It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
- The companies will share trial costs, and each retains development and commercial rights to its own drug.
Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.
Industry NewsAstraZeneca / Summit TherapeuticsFierce Biotech
AstraZeneca Takes a $2B Stake in Summit to Pair Ivonescimab with Its ADCs
- AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted).
- The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.
This is AstraZeneca buying a seat rather than a pipeline: equity plus combination rights instead of an acquisition or license, keeping it close to a PD-1xVEGF class it doesn't own without paying for the asset outright. The bet is that ADC plus PD-1xVEGF combinations become a next oncology backbone, with AstraZeneca's ADC portfolio as the partner of choice. The broader MOU is non-binding, so definitive terms are the thing to watch.
Industry NewsAkeso / Summit TherapeuticsEndpoints News
Ivonescimab Beats Keytruda on Survival in Phase 3 NSCLC Trial
- Ivonescimab (Akeso/Summit's PD-1 x VEGF bispecific) reduced risk of death by 27% vs. Merck's Keytruda in the Phase 3 HARMONi-2 trial.
- Trial enrolled treatment-naive, PD-L1-positive advanced NSCLC patients in China.
- Median overall survival: 30.75 months for ivonescimab vs. 22.57 months for Keytruda.
- Adds to the trial's earlier primary PFS win — a 49% reduction in progression/death risk (11.14 vs. 5.82 months).
- Fourth Phase 3 ivonescimab readout to hit its OS endpoint, bolstering the case for combining PD-1 blockade with anti-VEGF activity in one bispecific.
- Akeso (China) and Summit Therapeutics (ex-China licensee) are co-developing the drug as a head-to-head Keytruda challenger.
A head-to-head overall-survival win over Keytruda is about as rare an event as oncology drug development produces — Merck's franchise has fended off nearly every direct challenger for a decade, and ivonescimab is now four-for-four on OS across its Phase 3 program. That changes the calculus for Summit, whose ex-China license from Akeso looked speculative at signing and now looks like one of the shrewder biotech deals in recent memory — every data cut adds leverage for future pricing, partnering, or M&A conversations. It's also the clearest advertisement yet for the China-originated-asset licensing wave Western biotechs have been chasing: a domestically-developed bispecific outrunning the world's best-selling drug in its own trial. For Merck, it lands squarely as Keytruda nears patent cliff — this isn't a niche subtype win, it's a direct share threat in frontline NSCLC, the franchise's core indication.